Case report

Experience with adjuvant chemotherapy for pseudomyxoma peritonei secondary to mucinous adenocarcinoma of the appendix with oxaliplatin/fluorouracil/leucovorin (FOLFOX4)

Chin-Fan Chen^1,4 , Che-Jen Huang^1,3 , Wan-Yi Kang² and Jan-Sing Hsieh^1,3

¹  Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan

²  Department of Pathology, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan

³  Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan

⁴  Department of Surgery, Pingtung Hospital, Department of Health, Executive Yuan, Ping-Tung 900, Taiwan

author email corresponding author email

World Journal of Surgical Oncology 2008, 6:118doi:10.1186/1477-7819-6-118

Published:	11 November 2008

Abstract

Background

Pseudomyxoma peritonei (PMP) is a rare condition characterized by mucinous tumors, disseminated intra-peritoneal implants, and mucinous ascites. So far its diagnosis remains challenging to most clinicians.

Case presentation

A 55-year-old male patient had suffered from acute onset of abdominal pain and abdominal distension for one day prior to his admission. Physical examination revealed tenderness over the right lower quadrant of the abdomen without diffuse muscle guarding. A large amount of ascites was identified by abdominal computed tomography (CT) scan. Paracentesis showed the appearance of sticky mucinous ascites. He underwent laparotomy under the impression of pseudomyxoma peritonei. There was a lot of mucinous ascites, one appendiceal tumor and multiple peritoneal implants disseminated from the subphrenic space to the recto-vesicle pouch. Pseudomyxoma Peritonei caused by mucinous adenocarcinoma of appendiceal origin, was confirmed by histopathology. We performed an excision of the appendiceal tumor combined with copious irrigation and debridement. After the operation, he received 10 cycles of systemic chemotherapy with FOLFOX4 regimen, without specific morbidity. Follow-up of abdominal CT and colonoscopy at post-operative 17 months showed excellent response without evidence of local recurrence or distal metastasis. He made an uneventful recovery (up to the present) for 21 months after the operation.

Conclusion

This case report emphasizes the possible new role of systemic chemotherapy in the treatment of patients with this rare clinical syndrome.